Increased expression of the complement molecule, C5a, in NSCLC patients has been shown to activate signaling through its receptor, C5aR, and is associated with increased KLF5, GCN5, and GDF15 levels and promotion of A549 proliferation [35]. Here, KLF5 is linked to non-small cell lung carcinoma.